SEC Watching Press Releases, Wants Context For “Preliminary” Trial Results
Executive Summary
The Securities & Exchange Commission is concerned that press releases highlighting preliminary results from clinical drug trials are not putting the data into the context of the overall trial
You may also be interested in...
FDA/SEC Cooperation On Investor Communications To Be Headed By Taylor
FDA Associate Commissioner for Regulatory Affairs John Taylor will serve as the liaison with the Securities & Exchange Commission as FDA expands its role in regulating investor communications
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials